Protein Sciences

Latest Headlines

Latest Headlines

FDA green-lights a flu vaccine made with new technology

Five years after little Protein Sciences first went to the FDA in search of an approval of its innovative flu vaccine, regulators have finally agreed to hit the green light to permit the biotech to start marketing the jab.

Protein Sciences nabs Flublok approval

A little more than a month after taking over vacated manufacturing space in New York from Pfizer, Protein Sciences won regulatory approval from the FDA for a new type of flu vaccine.

Protein Sciences expands flu vaccine operations to Pfizer site

Protein Sciences will lease two buildings at Pfizer's Pearl River, NY, site to create a production line for its recombinant influenza vaccine Flublok.

Protein Sciences takes over fully equipped Wyeth vaccine plant

One way to start up a vaccine manufacturing operation is to simply take over a mothballed plant left idle by one of Big Pharma's merger shakeouts. That is exactly what Protein Sciences is doing in New York.

Protein Sciences to inhabit Pfizer facilities to make next-gen flu vaccine

The lease gives Meriden, CT-based Protein Sciences access to 83,000 square feet of space at Pfizer's 550-acre Pearl River campus, which has been subject to cutbacks within the past couple of years.

Fungi, caterpillars, plants, bacteria: New frontiers in vaccine production

CHANTILLY, VA- A popular topic at the World Vaccines Congress was cell-based alternatives to egg-based technologies, which was called the next frontier by Dr. Richard Schwartz of NIAID. In recent

Pharma turns to small developers for vax tech

Paul Bogorad at Putnam Associates is bullish about the vaccine business. Reviewing the now familiar story line about Big Pharma's embrace of vaccines after years of neglect, Mass High Tech relates

Vaccine makers struggle to modernize

Novartis cut the ribbon on a new North Carolina vaccines facility to munch fanfare Tuesday. However, products from the plant won't hit the shelves for a couple of years. Furthermore, high-speed

Caterpillar shot fails to win vote on safety

In a 6 to 5 vote, the FDA's Vaccines and Related Biological Products Advisory Committee has determined that Connecticut-based Protein Sciences hasn't proven that its innovative flu vaccine

Caterpillar-based flu shot could be on horizon

The FDA's Vaccines and Related Biological Products Advisory Committee today will determine whether Protein Sciences' flu vaccine FluBlok, which can be produced in less than two months by inserting